You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
以色列調查指接種第三劑「復必泰」副作用與第二劑相似
阿思達克 08-10 10:42
以色列研究顯示,大部分接種第三劑「復必泰」新冠疫苗出現的副作用,與接種第二劑時相似甚或減輕。當地早前已開始為60歲以上民眾接種第三劑疫苗,以減慢新冠變種Delta傳播。 以色列最大醫療機構Clalit表示,他們已為逾24萬名民眾接種第三劑「復必泰」疫苗,當中約4,500人接受調查,88%受訪者稱接種第三劑後感覺與接種第二劑相若或更好,31%受訪者稱出現副作用,主要為接種處酸痛,0.4%受訪者稱出現呼吸困難,1%稱接種後要求治療。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account